Why Bluebird Bio Stock Is Taking Flight Today

Why Bluebird Bio Stock Is Taking Flight Today

Shares of gene therapy company Bluebird Bio (NASDAQ: BLUE) were up by a healthy 12.4% on heavy volume as of 11:16 a.m. ET Friday morning. The biotech's stock appears to be getting a boost from both a broad upward trend across the biotechnology space today, as well as from rumors circulating on social media about a possible buyout. Bluebird scored two approvals from the Food and Drug Administration (FDA) earlier this year for its one-and-done gene therapies: Skysona for cerebral adrenoleukodystrophy (CALD) and Zynteglo for transfusion-dependent beta-thalassemia (TDT).